Compare ALEMBIC PHARMA with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA SUN PHARMA ALEMBIC PHARMA/
SUN PHARMA
 
P/E (TTM) x 17.5 80.5 21.7% View Chart
P/BV x 6.9 3.4 202.0% View Chart
Dividend Yield % 0.5 0.6 88.8%  

Financials

 ALEMBIC PHARMA   SUN PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
SUN PHARMA
Mar-20
ALEMBIC PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs664484 137.2%   
Low Rs412315 130.8%   
Sales per share (Unadj.) Rs208.7136.9 152.5%  
Earnings per share (Unadj.) Rs31.017.5 177.6%  
Cash flow per share (Unadj.) Rs37.126.0 142.7%  
Dividends per share (Unadj.) Rs5.504.00 137.5%  
Dividend yield (eoy) %1.01.0 102.1%  
Book value per share (Unadj.) Rs144.2188.7 76.4%  
Shares outstanding (eoy) m188.522,399.26 7.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.9 88.3%   
Avg P/E ratio x17.422.9 75.8%  
P/CF ratio (eoy) x14.515.4 94.4%  
Price / Book Value ratio x3.72.1 176.2%  
Dividend payout %17.722.9 77.4%   
Avg Mkt Cap Rs m101,461958,864 10.6%   
No. of employees `000NA17.8 0.0%   
Total wages/salary Rs m7,46763,624 11.7%   
Avg. sales/employee Rs ThNM18,490.6-  
Avg. wages/employee Rs ThNM3,582.6-  
Avg. net profit/employee Rs ThNM2,357.6-  
INCOME DATA
Net Sales Rs m39,347328,375 12.0%  
Other income Rs m946,360 1.5%   
Total revenues Rs m39,441334,735 11.8%   
Gross profit Rs m8,73669,898 12.5%  
Depreciation Rs m1,15220,528 5.6%   
Interest Rs m1843,027 6.1%   
Profit before tax Rs m7,49352,702 14.2%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m1,5688,228 19.1%   
Profit after tax Rs m5,84441,868 14.0%  
Gross profit margin %22.221.3 104.3%  
Effective tax rate %20.915.6 134.0%   
Net profit margin %14.912.8 116.5%  
BALANCE SHEET DATA
Current assets Rs m19,577316,542 6.2%   
Current liabilities Rs m14,896157,064 9.5%   
Net working cap to sales %11.948.6 24.5%  
Current ratio x1.32.0 65.2%  
Inventory Days Days9088 102.5%  
Debtors Days Days45105 43.3%  
Net fixed assets Rs m27,097243,102 11.1%   
Share capital Rs m3772,399 15.7%   
"Free" reserves Rs m26,811450,245 6.0%   
Net worth Rs m27,188452,645 6.0%   
Long term debt Rs m4,99320,289 24.6%   
Total assets Rs m47,778682,525 7.0%  
Interest coverage x41.718.4 226.5%   
Debt to equity ratio x0.20 409.7%  
Sales to assets ratio x0.80.5 171.2%   
Return on assets %12.66.6 191.8%  
Return on equity %21.59.2 232.4%  
Return on capital %23.611.2 210.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45374,219 26.2%   
Fx outflow Rs m6,06527,964 21.7%   
Net fx Rs m13,38846,255 28.9%   
CASH FLOW
From Operations Rs m8,12065,548 12.4%  
From Investments Rs m-7,556-25,888 29.2%  
From Financial Activity Rs m590-57,151 -1.0%  
Net Cashflow Rs m1,153-13,857 -8.3%  

Share Holding

Indian Promoters % 74.1 63.7 116.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 5.1 56.5%  
FIIs % 9.1 23.0 39.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 8.3 167.5%  
Shareholders   49,328 133,026 37.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   NATCO PHARMA  FRESENIUS KABI ONCO.  FDC  ABBOTT INDIA  STRIDES PHARMA SCIENCE  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Apr 16, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS